FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)



Compositions and methods of use
05/28/15 - 20150147315 - The present invention relates to a derivative bacterial strain of an avirulent, non-pathogenic Clostridium ghonii that is capable of arresting the growth of, regressing or destroying one or more solid tumours. The present invention further relates to a composition comprising the derivative bacterial strain for targeted lysis of solid tumours....

Cd33 antibodies and use of same to treat cancer
05/28/15 - 20150147316 - The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33....

Methods related to bevacizumab
05/28/15 - 20150147317 - The present invention relates to the characterization and production of bevacizumab....

Caninized anti-ngf antibodies and methods thereof
05/28/15 - 20150147318 - The invention provides novel caninized anti-NGF antibodies (such as caninized anti-NGF antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of NGF related disorders, particularly pain....

Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
05/28/15 - 20150147319 - A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided....

Ophthalmic drug delivery system containing phospholipid and cholesterol
05/28/15 - 20150147320 - An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes....

Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
05/28/15 - 20150147321 - A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present...

Compositions and methods for targeting type 1 interferon producing cells
05/28/15 - 20150147322 - The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds....

Methods of treating a disease or disorder associated with bruton's tyrosine kinase
05/21/15 - 20150139979 - The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK....

Detectors of serum biomarkers for predicting ovarian cancer recurrence
05/21/15 - 20150139980 - Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the...

Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica
05/21/15 - 20150139981 - Provided herein is a method of treating neuromyelitis optica (NMO) in an animal or human subject comprising administering to the subject a composition comprising a therapeutically effective amount of an Fc region modified anli-AQP4 antibody, thereby treating the NMO in the subject, in some embodiments, the Fc region modified anti-AQP4...

Anti-siglec-15 antibodies
05/21/15 - 20150139982 - Antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts. Compositions and cells expressing anti-Siglec-15 antibodies or antigen binding fragments are...

Use of blocking agents of bone morphogenic protein (bmp) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
05/21/15 - 20150139983 - The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the...

Active protease-resistant antibody fc mutants
05/21/15 - 20150139984 - The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with FcγR receptors except with FcγRI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them....

Novel compositions and methods for treating ige-mediated disorders
05/21/15 - 20150139985 - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma....

Ilt3 binding molecules and uses therefor
05/21/15 - 20150139986 - Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention....

Treatment of homozygous familial hypercholesterolemia
05/21/15 - 20150139987 - Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor....

Glycoengineered binding protein compositions
05/21/15 - 20150139988 - Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions....

Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
05/21/15 - 20150139989 - The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell...

Human monoclonal antibody
05/21/15 - 20150139990 - The invention provides a method for the prophylaxis, improvement, or treatment of inflammatory bowel disease, multiple sclerosis, and psoriasis by administering to a subject an effective amount of an isolated anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of amino acid numbers...

Anti-cd134 (ox40) antibodies and uses thereof
05/14/15 - 20150132288 - The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated...

Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy
05/14/15 - 20150132289 - A method or composition comprising an anti-CD3 immune molecule for treatment of PSC (primary sclerosing cholangitis) or PBC (primary biliary cirrhosis) in a subject....

Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
05/14/15 - 20150132290 - The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T...

Methods for treatment of gastric cancer
05/14/15 - 20150132291 - The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha....

Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
05/14/15 - 20150132292 - Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an...

Immunostimulatory sequence oligonucleotides and methods of using the same
05/14/15 - 20150132293 - The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides....

Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
05/14/15 - 20150132294 - The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying...

Methods and compositions for diagnosing, prognosing, and treating endometriosis
05/14/15 - 20150132295 - This document provides methods and materials related to genetic variations associated with endometriosis. For example, this document provides methods for using such genetic variations to assess risk of, or susceptibility of developing or diagnosing endometriosis....

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
05/14/15 - 20150132296 - Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed....

Survival predictor for diffuse large b cell lymphoma
05/14/15 - 20150132297 - The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients....

Gemcitabine prodrugs and uses thereof
05/14/15 - 20150132298 - and pharmaceutically acceptable salts thereof. For compounds of formula I, R1 and R2 are independently selected from the group consisting of H, —C(═O)—(CH2)2-aryl, and —C(═O)—(CH2)n—C(═O)—NH-aryl. The subscript n is from 2 to 6. R3 is selected from the group consisting of H and —C(═O)—O—R4; and R4 is selected from the...

Methods of treating neuronal inflammation using an il-31 monoclonal antibody
05/14/15 - 20150132299 - Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated....

Methods of antagonizing signal transduction in spinal cord cells using an il-31ra or osmr-b antagonist
05/14/15 - 20150132300 - Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated....

Combined therapeutic use of antibodies and endoglycosidases
05/07/15 - 20150125443 - The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is...

Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
05/07/15 - 20150125444 - Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent...

Compositions and methods for treating cancer
05/07/15 - 20150125445 - The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is...

Combination therapy of an anti cd20 antibody with a btk inhibitor
05/07/15 - 20150125446 - The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor....

Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
05/07/15 - 20150125447 - The present invention relates to pharmaceutical combinations CD33 antibodies and de-methylating agents for use in treating diseases like MDS and cancer, especially AML....

Method for predicting the response to her2-directed therapy
05/07/15 - 20150125448 - This invention provides methods for determining or predicting response to HER2-directed therapy in an individual....

Use of tau to monitor immunotherapy
04/30/15 - - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau....

Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof
04/30/15 - 20150118224 - Described herein are methods and kits for the detection of endothelial cell injury and/or activation and to the diagnostic of transplant antibody mediated rejection (ABMR). The invention further relates to methods and kits for diagnosing endothelial to mesenchymal transition (EndMT). In various embodiments, the methods comprise assessing expression of one,...

Anticoagulant antidotes
04/30/15 - 20150118225 - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants....

Antibodies directed against nerve growth factor (ngf)
04/30/15 - 20150118226 - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and...

Antibody fc mutants with ablated effector functions
04/30/15 - 20150118227 - Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders....

Modulated lysine variant species compositions and methods for producing and using the same
04/23/15 - 20150110775 - The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in...

Antibodies that recognize iapp
04/23/15 - 20150110776 - The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome,...

Antibodies that recognize iapp
04/23/15 - 20150110777 - The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome,...

Compositions comprising mg53 and methods for the treatment and prevention of airway injury
04/23/15 - 20150110778 - Disclosed herein are compositions and methods for the treatment and/or protection of airway cells and/or tissue from damage due to injury to the lungs or complications of underlying respiratory, cardiovascular or infectious diseases, or any combination thereof....

Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
04/23/15 - 20150110779 - The invention described herein relates to diagnostic and therapeutic methods and compositions useful for predicting the likelihood a cancer patient will experience a gastrointestinal immune-related adverse event (GI-irAE) after administration of a pharmaceutically acceptable amount of an activator of the immune system....

Treatment of brain cancer
04/23/15 - 20150110780 - Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein....

Compositions and methods related to the prevention and treatment of rabies infection
04/23/15 - 20150110781 - The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection....

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
04/23/15 - 20150110782 - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the...

Antagonist anti-cd40 antibody pharmaceutical compositions
04/23/15 - 20150110783 - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and...

Therapeutic combinations and methods including irm compounds
04/23/15 - 20150110784 - The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component....

Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
04/23/15 - 20150110785 - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders....

Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence
04/16/15 - 20150104442 - Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a...

Anti-erbb2 antibody variants
04/16/15 - 20150104443 - The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with...

Methods related to trastuzumab
04/16/15 - 20150104444 - The present invention relates to the characterization and production of trastuzumab. The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) trastuzumab. In some instances, methods herein allow highly resolved evaluation of trastuzumab useful for, inter alia, manufacturing trastuzumab, characterizing trastuzumab, identifying and/or confirming trastuzumab, monitoring...

Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
04/16/15 - 20150104445 - Methods and compositions are provided for treating diseases implicating alternative pathway complement immune system activation....

Genetic and environmental markers to identify infants at risk for severe lung disease
04/16/15 - 20150104446 - Provided herein are methods and compositions for determining the susceptibility of infants to severe respiratory syncytial virus (RSV) infections. Also provide are methods of treating said subjects prophylactically to reduce the incidence of such infections....

Methods for treating chronic obstructive pulmonary disease using benralizumab
04/16/15 - 20150104447 - Provided herein is are methods of treating Chronic Obstructive Pulmonary Disease (COPD) in a patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof....

Anti-complement c1s antibodies and uses thereof
04/16/15 - 20150104448 - The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions....

Variant immunoglobulins with improved manufacturability
04/16/15 - 20150104449 - This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced...

Identification of genetic variants
04/09/15 - 20150098937 - The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or...

Modulators of acyl-coa lysocardiolipin acyltransferase 1 (alcat1) and uses thereof
04/09/15 - 20150098938 - Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided....

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
04/09/15 - 20150098939 - The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab...

Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
04/09/15 - 20150098940 - The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided....

Anti-glypican-3 antibody
04/09/15 - 20150098941 - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues....

Methods for inhibiting ocular angiogenesis
04/02/15 - 20150093375 - The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders....

Combination therapy of an afucosylated cd20 antibody with bendamustine
04/02/15 - 20150093376 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine....

Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
04/02/15 - 20150093377 - The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or...

Goodpasture antigen binding protein detection and inhibition and its use in diabetes
04/02/15 - 20150093378 - Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2...

Novel compositions and methods for treating ige-mediated disorders
04/02/15 - 20150093379 - The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma....

Immunopotentiative composition
04/02/15 - 20150093380 - The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment....

Fixed dosing of her antibodies
04/02/15 - 20150093381 - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab....

Advertise on FreshPatents.com - Rates & Info

###

FreshPatents.com Support - Terms & Conditions